Innovation

Development Pipeline

Development Pipeline

We are determined to drive breakthrough innovations for patients in diseases of high unmet medical need. In clinical development we are currently advancing 35 projects that we review regularly so that we can give priority to the most promising programs.

Pipeline Overview

The following table lists a selection of major Pharma portfolio projects that we are advancing through different stages of development. Click on a project for further information.

 

More detailed information on individual programs, therapeutic areas, and development timelines as well as a one-page overview of our development portfolio can be found in our overview package for download.

 

Phases

Number of programs in clinical development.

 

A woman in a white shirt smiles at the camera.
Dr. Julia Schulze
PhaseAreaProgram (Mode-of-action)Indication 
IIIONCDarolutamide
(AR Inhibitor)
Adjuvant Prostate Cancersmall molecule
IIIONCDarolutamide
(AR Inhibitor)
Prostate Cancer with
Biochemical Recurrence after
Curative Radiotherapy
small molecule
IIIONCSevabertinib (HER2/mEGFR Inhibitor)Advanced Non-small
Cell Lung Cancer with
HER2 Activating Mutations, 1L
Small Molecule

 

IIICVRFinerenone
(MR Antagonist)
Non-diabetic CKD
(FIND-CKD)
small molecule
IIICVRFinerenone
(MR Antagonist)
Chronic Kidney Disease 
in Type 1 Diabetes 
(FINE-ONE)
small molecule
IIICVRVericiguat
(sGC Stimulator)
Heart Failure
(HFrEF)
small molecule
IIICVRAsundexian
(FXIa Inhibitor)
2 Stroke Prevention
(OCEANIC Stroke)
 
small molecule
IIINRDBemdaneprocel (Cell Therapy)Parkinson's Disease
(exPDite-2)
Cell Therapy_NTE
IIIOthersMirena
(Levonorgestrel-releasing Intrauterine System)
Endometrial Hyperplasia (SUNFLOWER)small molecule
IIIOthers124I-Evuzamitide
(PET Tracer)
Diagnosis of Cardiac Amyloidosis (REVEAL)Imaging Agent
IIONCSevabertinib (HER2/mEGFR Inhibitor)Metastatic or Unresectable Solid Tumors with HER2-activating Mutations (PanSOHO)small molecule
IICVRCongestive Heart Failure AAV Gene Therapy (AB-1002)Congestive Heart Failure
(GenePHIT)
gene therapy
IICVRInclocibart (Anti-a2AP)Acute Ischemic Stroke;
Pulmonary Embolism
(SIRIUS)
Protein Therapy
IICVRNurandociguat
(sGC Activator Oral)
Chronic Kidney Disease
(ALPINE-1)
small molecule
IICVRSEMA 3aAlport Syndrome (ASSESS)Protein Therapy
IINRDParkinson's Disease
AAV Gene Therapy
(AB-1005)
Parkinson's Disease
(REGENERATE-PD)
Genetic Therapy
IONCVVD Keap1 ActAdvanced Solid Tumorssmall molecule
IONC225Ac-PelgifatamabAdvanced Prostate CancerRadiotherapy_NTE
IONC225Ac-PSMA-TrilliumAdvanced Prostate CancerRadiotherapy_NTE
IONCSOS1 InhibitorAdvanced Solid Cancerssmall molecule
IONCPRMT5 InhibitorMTAP-deleted Solid Tumorssmall molecule
IONCVVD RAS-PI3K InhibitorAdvanced Solid Tumorssmall molecule
IONC225Ac-GPC3Advanced Liver CancerRadiotherapy_NTE
IONCVVD WRN InhibitorAdvanced Solid Tumorssmall molecule
IONCKRAS G12D InhibitorAdvanced Solid Tumorssmall molecule
ICVRDual FIIa/Xa InhibitorAnti-coagulationsmall molecule
ICVRGIRK4 InhibitorAtrial fibrillationNew Melecular Entity
ICVRBAY 3620122Vasoplegiasmall molecule
INRDMultiple System Atrophy
AAV Gene Therapy
Multiple
System Atrophy
Gene Therapy_NTE
INRDPompe Disease
AAV Gene Therapy
Pompe DiseaseGene Therapy_NTE
INRDLGMD2I/R9
AAV Gene Therapy
Limb Girdle
Muscular Dystrophy
Gene Therapy_NTE
IOthersGPR84 AntagonistDiabetic
Neuropathic Pain
small molecule
IOthersBAY 2701250Pulmonary HypertensionProtein Therapy
IOthersPrimary Photoreceptor Diseases
Cell Therapy
Primary Photoreceptor DiseaseCell Therapy_NTE
IOthersAT-05 SPECT TracerDiagnosis of Cardiac Amyloidosisimaging agent

 

legende

 

New Molecular Entity   New molecular entity
Life cycle management   Life cycle management

 

Derin Denham
Derin Denham